These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 31070750)

  • 21. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
    Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
    Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Yamada K; Ichiki M; Takahashi K; Hisamatsu Y; Takeoka H; Azuma K; Shukuya T; Nishikawa K; Tokito T; Ishii H; Hoshino T
    Cancer Chemother Pharmacol; 2016 Sep; 78(3):501-7. PubMed ID: 27402398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ciuleanu T; Tsai CM; Tsao CJ; Milanowski J; Amoroso D; Heo DS; Groen HJ; Szczesna A; Chung CY; Chao TY; Middleton G; Zeaiter A; Klingelschmitt G; Klughammer B; Thatcher N
    Lung Cancer; 2013 Nov; 82(2):276-81. PubMed ID: 23992877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 2 study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naive patients with advanced nonsquamous non-small cell lung cancer.
    Urata Y; Okamoto I; Takeda M; Hattori Y; Okuno K; Shimada T; Kurata T; Kaneda H; Miyazaki M; Terashima M; Tanaka K; Morita S; Nakagawa K; Negoro S; Satouchi M
    Cancer; 2013 Jun; 119(12):2275-81. PubMed ID: 23558513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H; Zvirbule Z; De Braud F; Kingsley CD; Mekhail T; Lowe T; Schütte W; Lena H; Lawler W; Braiteh F; Cosgriff T; Kaen D; Boyer M; Hsu J; Phan S; Novello S
    Clin Lung Cancer; 2017 Jan; 18(1):50-59. PubMed ID: 27856142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.
    Lai CL; Wei YF; Hsia TC; Chang GC; Wu JT; Chen JY; Chen YM
    Asia Pac J Clin Oncol; 2020 Apr; 16(2):e68-e73. PubMed ID: 31773897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
    Ouyang X; Shi M; Jie F; Bai Y; Shen P; Yu Z; Wang X; Huang C; Tao M; Wang Z; Xie C; Wu Q; Shu Y; Han B; Zhang F; Zhang Y; Hu C; Ma X; Liang Y; Wang A; Lu B; Shi Y; Chen J; Zhuang Z; Wang J; Huang J; Wang C; Bai C; Zhou X; Li Q; Chen F; Yu H; Feng J
    Invest New Drugs; 2018 Apr; 36(2):315-322. PubMed ID: 29134432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line pemetrexed/carboplatin or cisplatin/bevacizumab compared with paclitaxel/carboplatin/bevacizumab in patients with advanced non-squamous non-small cell lung cancer with wild-type driver genes: A real-world study in China.
    Chang Q; Zhang Y; Xu J; Zhong R; Qiang H; Zhang B; Han B; Qian J; Chu T
    Thorac Cancer; 2019 May; 10(5):1043-1050. PubMed ID: 30900826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC; Adjei AA; Bahleda R; Besse B; Ferte C; Planchard D; Zhou J; Ware J; Morrissey K; Shankar G; Lin W; Schutzman JL; Dy GK; Groen HJM
    Eur J Cancer; 2017 Nov; 86():186-196. PubMed ID: 28992562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
    Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
    Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of vinorelbine plus cisplatin and S-1 plus cisplatin in concurrent chemoradiotherapeutic regimens for unresectable stage III non-small cell lung cancer.
    Shukuya T; Takahashi T; Harada H; Akamatsu H; Sakaguchi C; Imai H; Ono A; Nakamura Y; Tsuya A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi K; Yamamoto N
    Anticancer Res; 2012 Feb; 32(2):675-80. PubMed ID: 22287762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative chemoradiotherapy using cisplatin plus S-1 can induce downstaging in patients with locally advanced (stage III) non-small-cell lung cancer.
    Kato M; Onishi H; Matsumoto K; Tsuruta N; Higuchi K; Motoshita J; Katano M
    Anticancer Res; 2012 Nov; 32(11):5099-104. PubMed ID: 23155287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
    Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
    Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer.
    Takiguchi Y; Iwasawa S; Minato K; Miura Y; Gemma A; Noro R; Yoshimori K; Shingyoji M; Hino M; Ando M; Okamoto H
    Int J Clin Oncol; 2015 Aug; 20(4):659-67. PubMed ID: 25301566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.